Alterity Therapeutics
在场
Alterity Therapeutics 是一家在股票代码 ATH (US) 下上市的公司。
高管
查看带有其 7 名主要高管的组织结构图
Alterity Therapeutics 搜索最多的简介
- David Stamler, Chief Executive Officer
- Lawrence Gozlan, Non Executive Director
- Geoffrey Kempler, Non-Executive Chairman
高管在Alterity Therapeutics变化
- Abby Macnish Niven已作为Chief Financial Officer加入公司 (新闻发布的2024九月30号).
- Phillip Hains, Chief Financial Officer, 已经离开公司 (新闻发布的2024九月30号).
创建提醒
跟踪 Alterity Therapeutics 的高管变动
药店
Alterity Therapeutics 拥有 1,835 家竞争者，其中包括 Pfizer (美国(美洲))、Johnson & Johnson (美国(美洲)) 和 Sanofi (法国)。
Popular M&A news in 药店
- Grace Therapeutics将在Oct 24, 2024将其名称改为Grace Therapeutics。 (公布2024十月27号).
- Orasis Pharmaceuticals 刚刚宣布为 78 筹款数百万美元。 (公布2024十月21号).
- Lundbeck has announced the acquisition of Longboard Pharmaceuticals (公布2024十月17号).
药店 行业的其他推荐联系人
消息
Alterity Therapeutics 的最新新闻稿
- Alterity to Participate in a Fireside Chat at the 2024 Maxim Healthcare Virtual Summit on 17 October 2024 - Alterity Therapeutics
- Alterity Therapeutics Announces Presentation of New Data Describing Neuroprotection of ATH434 at Neuroscience Meeting - Alterity Therapeutics
- Alterity Therapeutics Raises Profile with Multiple Data Presentations at the International Congress of Parkinson’s Disease and Movement Disorders® - Alterity Therapeutics
- Alterity Therapeutics Appoints Abby Macnish Niven as Chief Financial Officer - Alterity Therapeutics
- XBRL 30 June 2024 filed with the SEC - Alterity Therapeutics
- News - Alterity Therapeutics
- Alterity Therapeutics to Deliver Multiple Oral and Poster Presentations at the International Congress of Parkinson’s Disease and Movement Disorders® - Alterity Therapeutics
- Appendix 4C – Q4 FY24 Quarterly Cash Flow Report - Alterity Therapeutics
- Alterity Therapeutics to Present at MST Financial Webinar - Alterity Therapeutics
- Alterity Therapeutics Reports Positive Interim Data from ATH434-202 Phase 2 Clinical Trial in Multiple System Atrophy - Alterity Therapeutics
- View more press releases Close
通过电子邮件
